Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 05, 2023 16:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals to Highlight 2023 Priorities and Clinical Milestones at the 41st Annual J.P. Morgan Healthcare Conference

Plans to advance diverse pipeline of five disclosed programs in oncology and metabolic diseases Expects to initiate proof of concept trials in CML and obesity and to report top-line data from DUET,...
December 23, 2022 16:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Announces Closing of Public Offering of Shares of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

FOSTER CITY, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
December 20, 2022 19:40 ET | Source: Terns Pharmaceuticals, Inc.

Terns Announces Pricing of $75 Million Public Offering

FOSTER CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
December 20, 2022 08:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
December 19, 2022 16:31 ET | Source: Terns Pharmaceuticals, Inc.

Terns Announces Proposed Public Offering

FOSTER CITY, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
December 01, 2022 16:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals to Present at the 2022 JMP Securities Hematology and Oncology Summit

FOSTER CITY, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
November 09, 2022 16:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights

Terns plans to initiate U.S. clinical trial for TERN-701 (allosteric BCR-ABL inhibitor) in CML in second half of 2023Positive data from Phase 1 trial of TERN-501 (THR-β agonist) in NASH presented at...
November 04, 2022 08:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals Highlights Results from Phase 1 Clinical Trial of TERN-501 at AASLD The Liver Meeting® 2022

Data demonstrated treatment with TERN-501 resulted in time- and dose-dependent increases in sex hormone binding globulin (SHBG), a key marker linked to NASH histologic efficacy Phase 2a DUET trial...
October 26, 2022 16:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals to Present Positive Clinical Data in NASH at AASLD The Liver Meeting® 2022

FOSTER CITY, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
October 11, 2022 16:05 ET | Source: Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals to Present at the H. C. Wainwright 6th Annual NASH Investor Conference

FOSTER CITY, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...